الملخص
Bone metabolism disorders are characterized by an imbalance of bone resorption and formation in the bone remodeling process. Glucocorticoids that are used to treat kidney diseases exacerbate these disorders. P-selectin and galectin-3 are molecules involved in the sclerotic process in kidney, whereas bone resorption is regulated by the interaction between the nuclear factor activator kappa b receptor (RANK), its ligand (RANKL) and the RANKL decoy receptor osteoprotegerin (OPG). The aim of this study was to investigate the cellular and molecular mechanisms of disruption of bone remodeling regulation processes, reflected by intercellular mediators (RANKL, OPG, P-selectin and galectin-3) in chronic kidney disease experimental model treated with glucocorticoids. Rats were divided into four groups of 10 animals each. The first group, the control group, included intact animals. The second group consisted of rats with impaired bone remodeling resulting from chronic kidney disease (experimental group (CKD). The third group was a group of animals with impaired bone remodeling due to exposure to glucocorticoids (experimental group (GCs)). The fourth group consisted of rats with impaired bone remodeling in chronic kidney disease, followed by exposure to glucocorticoids (experimental group (CKD + GCs)). The effects of CKD and glucocorticoid were evaluated biochemically, histologically and by measuring bone density. An enzymelinked immunoassay was used to measure intercellular mediator levels in the serum. The bone density in the experimental groups was reduced compared to the control group. RANKL levels in animals of three experimental groups were higher than in intact animals. Serum levels of OPG were higher in CKD and GCs groups than in intact animals. At the same time, in the animals' blood serum of the CKD + GCs group, the levels of OPG were lower, than those in animals from the control group. The levels of galectin-3 in the serum of the experimental groups GCs and CKD + GCs were lower than in intact animals. The serum levels of galectin-3 in animals of the CKD group were higher than those in animals from the control group. The levels of P-selectin were lower in the serum of the GCs group than in intact animals. At the same time, the levels of P-selectin were higher in the CKD and CKD + GCs groups, than those in animals from the control group. In conclusion, the study of the complex system of bone remodeling regulation, which includes many factors and their interactions, may lead to the development of new methods for treating patients with chronic kidney disease in order to prevent osteoporosis in the future. (AU)
Las enfermedades metabólicas óseas se caracterizan por un desequilibrio en el proceso de remodelación ósea en los que participan mediadores tales como receptor del activador del factor nuclear- kappa- b (RANK), su ligando (RANKL) y la osteoprotegerina (OPG). Los glucocorticoides, recuentemente empleados en el tratamiento de la enfermedad renal crónica, exacerban este desequilibrio. En la enfermedad esclerótica renal, las moléculas de adhesión celular P-selectina and galectina-3 tienen un rol fundamental. El objetivo de esta trabajo fue estudiar las alteraciones en los mediadores de la remodelación ósea (RANKL, OPG, P-selectina and galectina-3) en un modelo de enfermedad renal crónica con tratamiento glucocorticoideo. Ratas Wistar hembras fueron divididos en 4 grupos: control (C); enfermedad renal crónica con afección de la remodelación ósea (ERC); animales con afección de la remodelación ósea expuestos a glucocorticoides (GC); enfermedad renal crónica con afección de la remodelación ósea tratados con glucocorticoides (ERC+GC). Los efectos de la ERC y los GC fueron evaluados bioquímicamente, histológicamente y por medición de la densidad ósea. RANKL, OPG, Pselectina and galectina-3 se cuantificaron en muestras de sangre venosa empleando enzimoinmuno análisis. En los 3 grupos experimentales la densidad ósea se evidenció reducida y los niveles séricos de RANKL elevados respecto al grupo control. Los niveles de OPG en los grupos ERC y GC fueron superiores mientras que en el grupo ERC+GC menores respecto a los animales controles. Galectina 3 plasmática en GC y ERC+GC se encontró reducida y aumentada en los animales ERC, en comparación con los animales controles. La concentración sérica de P-selectina sérica fue mayor en los grupos ERC y ERC+GC, y menor en los animales GC respecto a los niveles plasmáticos de los animales intactos. El avance del conocimiento sobre la regulación de la remodelación ósea a través de la interacción de mediadores sistémicos, en un futuro, puede conducir al desarrollo de nuevas estrategias terapéuticas para la prevención de la osteoporosis en pacientes con enfermedad renal crónica. (AU)
الموضوعات
Animals , Rats , Chronic Kidney Disease-Mineral and Bone Disorder/chemically induced , Bone Remodeling/drug effects , Kidney Diseases/physiopathology , Osteoporosis/prevention & control , Bone Diseases, Metabolic/diagnosis , Dexamethasone/administration & dosage , Bone Density/drug effects , Chloroform/therapeutic use , Rats, Wistar , P-Selectin/drug effects , P-Selectin/blood , Galectin 3/drug effects , Galectin 3/blood , RANK Ligand/drug effects , RANK Ligand/blood , Osteoprotegerin/drug effects , Osteoprotegerin/blood , Glucocorticoids/adverse effects , Glycerol/administration & dosage , Kidney Diseases/drug therapyالملخص
ABSTRACT Objective The aim of this study was to investigate the in vitro and in vivo biological responses to nanostructured carbonated hydroxyapatite/calcium alginate (CHA) microspheres used for alveolar bone repair, compared to sintered hydroxyapatite (HA). Material and Methods The maxillary central incisors of 45 Wistar rats were extracted, and the dental sockets were filled with HA, CHA, and blood clot (control group) (n=5/period/group). After 7, 21 and 42 days, the samples of bone with the biomaterials were obtained for histological and histomorphometric analysis, and the plasma levels of RANKL and OPG were determined via immunoassay. Statistical analysis was performed by Two-Way ANOVA with post-hoc Tukey test at 95% level of significance. Results The CHA and HA microspheres were cytocompatible with both human and murine cells on an in vitro assay. Histological analysis showed the time-dependent increase of newly formed bone in control group characterized by an intense osteoblast activity. In HA and CHA groups, the presence of a slight granulation reaction around the spheres was observed after seven days, which was reduced by the 42nd day. A considerable amount of newly formed bone was observed surrounding the CHA spheres and the biomaterials particles at 42-day time point compared with HA. Histomorphometric analysis showed a significant increase of newly formed bone in CHA group compared with HA after 21 and 42 days from surgery, moreover, CHA showed almost 2-fold greater biosorption than HA at 42 days (two-way ANOVA, p<0.05) indicating greater biosorption. An increase in the RANKL/OPG ratio was observed in the CHA group on the 7th day. Conclusion CHA spheres were osteoconductive and presented earlier biosorption, inducing early increases in the levels of proteins involved in resorption.
الموضوعات
Humans , Animals , Male , Alginates/pharmacology , Biocompatible Materials/pharmacology , Bone Regeneration/drug effects , Durapatite/pharmacology , Nanostructures/therapeutic use , Cell Count , Glucuronic Acid/pharmacology , Hexuronic Acids/pharmacology , Materials Testing , Osteoblasts/drug effects , Osteoprotegerin/blood , Rats, Wistar , Receptor Activator of Nuclear Factor-kappa B/blood , Reproducibility of Results , Time Factors , Tooth Socket/drug effects , X-Ray Diffractionالملخص
SUMMARY Introduction: osteoprotegerin has emerged as a new candidate for the treatment of osteoporosis. However, high levels of osteoprotegerin have been linked to vascular calcification, an independent and well-defined risk factor for cardiovascular disease (CVD) and mortality. Thus, the action of osteoprotegerin in these situations has been questioned. Objective: to evaluate the effect of osteoprotegerin (OPG) on the human body, especially in bone tissue and in vascular diseases. Methods: the scientific databases consulted were PubMed-Medline and Cochrane, using keywords (MeSH terms) grouped into the following syntaxes: (Osteoprotegerin OR Osteoclastogenesis Inhibitory Factor OR Receptors, Tumor Necrosis Factor, Member 11b OR Tumor Necrosis Factor Receptor Superfamily, Member 11b OR FDCR-1 Protein OR FDCR 1 Protein OR OCIF Protein OR Follicular Dendritic Cell-Derived Receptor-1) AND (Bones AND Bone OR Bones AND Bone Tissue OR Bones OR Bone Tissue OR Cardiovascular Diseases). Results: Osteoprotegerin is present in various organs and binds to two ligands: nuclear factor kB (RANKL) related to the differentiation of osteoclasts, and tumor necrosis factor related to the apoptosis-inducing ligand (TRAIL). OPG inhibits the regulation effects of nuclear factor kB on inflammation and on the skeletal and vascular systems, preventing the apoptosis induced by TRAIL, being related to the preservation of bone tissue. Conclusion: a deeper knowledge of the mechanisms involved in the association between OPG serum levels, bone integrity and cardiovascular disease can provide important data for future therapeutic interventions.
RESUMO Introdução: a osteoprotegerina (OPG) tem surgido como uma nova candidata para o tratamento da osteoporose; no entanto, níveis elevados de OPG têm sido relacionados à calcificação vascular, um fator de risco independente e bem definido para doença cardiovascular (DCV) e mortalidade. Assim, a ação da OPG nessas situações tem sido questionada. Objetivo: avaliar a ação da OPG no corpo humano, em especial no tecido ósseo e nas doenças vasculares. Métodos: as bases de informação científica consultadas foram PubMed-Medline e Cochrane, utilizando-se palavras-chave (MeSH terms) agrupadas nas seguintes sintaxes: (Osteoprotegerin OR Osteoclastogenesis Inhibitory Factor OR Receptors, Tumor Necrosis Factor, Member 11b OR Tumor Necrosis Factor Receptor Superfamily, Member 11b OR FDCR-1 Protein OR FDCR 1 Protein OR OCIF Protein OR Follicular Dendritic Cell-Derived Receptor-1) AND (Bones AND Bone OR Bones AND Bone Tissue OR Bones OR Bone Tissue OR Cardiovascular Diseases). Resultados: a OPG está presente em vários órgãos e une-se a dois ligantes: o fator nuclear kB (RANKL), relacionado com a diferenciação dos osteoclastos, e o fator de necrose tumoral, relacionado ao ligante indutor de apoptose (TRAIL). Assim, a OPG inibe os efeitos da regulação do fator nuclear kB na inflamação e nos sistemas esquelético e vascular, prevenindo a apoptose induzida pelo TRAIL, estando relacionada com a preservação do tecido ósseo. Conclusão: um conhecimento mais aprofundado sobre os mecanismos envolvidos na associação entre os níveis séricos da OPG, integridade óssea e doenças cardiovasculares podem proporcionar dados importantes para futuras intervenções terapêuticas.
الموضوعات
Female , Humans , Bone and Bones/metabolism , Osteoprotegerin/blood , Bone Remodeling/physiology , Cardiovascular Diseases/blood , Cardiovascular Diseases/metabolism , Osteoprotegerin/metabolism , RANK Ligand/metabolism , Risk Factors , TNF-Related Apoptosis-Inducing Ligand/metabolism , Vascular Calcification/blood , Vascular Calcification/metabolismالملخص
Osteoprotegerin (OPG) regulates bone mass by inhibiting osteoclast differentiation and activation, and plays a role in vascular calcification. We evaluated the relationship between osteoprotegerin levels and inflammatory markers, atherosclerosis, and mortality in patients with stages 3-5 chronic kidney disease. A total of 145 subjects (median age 61 years, 61% men; 36 patients on hemodialysis, 55 patients on peritoneal dialysis, and 54 patients with stages 3-5 chronic kidney disease) were studied. Clinical characteristics, markers of mineral metabolism (including fibroblast growth factor-23 [FGF-23]) and inflammation (high-sensitivity C-reactive protein [hsCRP] and interleukin-6 [IL-6]), and the intima-media thickness (IMT) in the common carotid arteries were measured at baseline. Cardiac function was assessed by color tissue Doppler echocardiography. After 36 months follow-up, the survival rate by Kaplan-Meier analysis was significantly different according to OPG levels (χ 2=14.33; P=0.002). Increased OPG levels were positively associated with IL-6 (r=0.38, P<0.001), FGF-23 (r=0.26, P<0.001) and hsCRP (r=0.0.24, P=0.003). In addition, OPG was positively associated with troponin I (r=0.54, P<0.001) and IMT (r=0.39, P<0.0001). Finally, in Cox analysis, only OPG (HR=1.07, 95%CI=1.02-1.13) and hsCRP (HR=1.02, 95%CI=1.01-1.04) were independently associated with increased risk of death. These results suggested that elevated levels of serum OPG might be associated with atherosclerosis and all-cause mortality in patients with chronic kidney disease.
الموضوعات
Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Atherosclerosis/complications , Osteoprotegerin/blood , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/mortality , Biomarkers/blood , Brazil/epidemiology , C-Reactive Protein/analysis , Carotid Intima-Media Thickness , Cause of Death , Echocardiography, Doppler/methods , Fibroblast Growth Factors/analysis , Heart Function Tests , /analysis , Kaplan-Meier Estimate , Multivariate Analysis , Risk , Severity of Illness Indexالملخص
BACKGROUND/AIMS: Osteoprotegerin (OPG) and fetuin-A are vascular calcification regulators that may be related to high cardiovascular (CV) mortality in hemodialysis (HD) patients. We evaluated the relationship between OPG, fetuin-A, and pulse wave velocity (PWV), a marker of vascular stiffness, and determined whether OPG and fetuin-A were independent predictors of CV events in HD patients. METHODS: We conducted a prospective observational study in 97 HD patients. OPG and fetuin-A were measured at baseline and arterial stiffness was evaluated by PWV. All patients were stratified into tertiles according to serum OPG levels. RESULTS: A significant trend was observed across increasing serum OPG concentration tertiles for age, HD duration, systolic blood pressure, cholesterol, triglycerides, and PWV. Multiple linear regression analysis revealed that diabetes (beta = 0.430, p = 0.000) and OPG levels (beta = 0.308, p = 0.003) were independently associated with PWV. The frequency of new CV events was significantly higher in the upper OPG tertiles compared with those in the lower OPG tertiles. In Cox proportional hazards analysis, upper tertiles of OPG levels were significantly associated with CV events (hazard ratio = 4.536, p = 0.011). CONCLUSIONS: Serum OPG, but not fetuin-A, levels were closely associated with increased vascular stiffness, and higher OPG levels may be independent predictors of new CV events in HD patients.
الموضوعات
Adult , Aged , Female , Humans , Male , Middle Aged , Biomarkers/blood , Cardiovascular Diseases/blood , Kaplan-Meier Estimate , Linear Models , Multivariate Analysis , Osteoprotegerin/blood , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Prospective Studies , Pulse Wave Analysis , Renal Dialysis/adverse effects , Renal Insufficiency, Chronic/complications , Risk Factors , Up-Regulation , Vascular Stiffness , alpha-2-HS-Glycoprotein/analysisالملخص
No abstract available.
الموضوعات
Female , Humans , Male , Cardiovascular Diseases/etiology , Osteoprotegerin/blood , Renal Dialysis , Renal Insufficiency, Chronic/therapy , Vascular Stiffnessالملخص
The aim of the present study was to investigate the association of serum osteoprotegerin [OPG] level with the presence of angiographically documented asymptomatic coronary artery disease [CAD] in patients with rheumatoid arthritis [RA] and to evaluate its relationship with plasma thrombomodulin [TM], as a marker of endothelial dysfunction and with carotid artery intima media thickness [IMT], as a marker of atherosclerosis. The study included 20 rheumatoid patients without CAD [negative results on exercise ECG stress test] and other 20 rheumatoid patients with CAD [positive results on exercise ECG stress test and confirmed by coronary angiography]. In addition, 20 age and sex matched normal control subjects were studied. Serum OPG and plasma TM levels were measured and carotid artery IMT was determined. The study revealed that serum OPG levels were significantly higher in rheumatoid patients with and without CAD than in controls [P < 0.001,P < 0.01; respectively] and were positively correlated with age, duration of disease, Disease active score 28[DAS28], Erythrocyte sedimentation rate [ESR], C-reactive protein [CRP] and carotid IMT in rheumatoid patients with and without CAD. Serum OPG level was correlated significantly with plasma TM only in rheumatoid patients with CAD [P < 0.001]. Osteoprotegerin is a clinically important molecule independently associated with the presence of coronary artery disease and may be a good indicator of atherosclerotic vascular damage and macroangiopathy in asymptomatic rheumatoid patients. Hence, measurement of serum OPG merits further investigation as a simple test for improving early diagnosis of asymptomatic CAD in rheumatoid patients
الموضوعات
Humans , Male , Female , Osteoprotegerin/blood , Thrombomodulin/blood , Coronary Artery Disease/diagnosis , Coronary Angiography/methodsالملخص
Bone mass loss is a major complication of chronic cholestatic liver disease (CCD). However, the long-term impact of CCD on bone mass acquisition is unknown. We longitudinally assessed bone mineral density (BMD) and factors involved in bone remodeling in 9 children and adolescents with CCD Child-Pugh A (5 boys/4 girls) and in 13 controls (6 boys/7 girls). The groups were evaluated twice, at baseline (T0) and after 3 years (T1), when osteocalcin, deoxypyridinoline, 25-hydroxyvitamin-D, parathyroid hormone, insulin-like growth factor-I (IGF-I), and BMD (L1-L4, proximal femur and total body) were determined. Serum levels of receptor activator for nuclear factor kB ligand (RANKL) and osteoprotegerin were measured only at T1. Lumbar spine BMD was reanalyzed twice: after adjustment for bone age and to compensate for the height factor. Volumetric density was also estimated mathematically in L2-L4. The BMD of L1-L4 was lower in the CCD group (Z-score at T0: control = -1.2 ± 0.8 vs CCD = -2.2 ± 1.4, P < 0.05; T1: control = -0.7 ± 0.8 vs CCD = -2.1 ± 1.1, P < 0.05). Osteocalcin and deoxypyridinoline were similar for the two groups. The CCD group presented lower IGF-I (Z-score at T1: control = 1.4 ± 2.8 vs CCD = -1.5 ± 1.0, P < 0.05) and RANKL (control = 0.465 ± 0.275 vs CCD = 0.195 ± 0.250 pM, P < 0.05) than control. Children with compensated CCD Child-Pugh A showed early impairment of bone acquisition, with the impact being more severe in an initial phase and then tapering in a slowly progressive way. Reduction in endocrine IGF-I has a crucial role in this process.
الموضوعات
Adolescent , Child , Female , Humans , Male , Bone Diseases, Metabolic/etiology , Cholestasis, Intrahepatic/complications , Bone Density , Bone Remodeling , Bone Diseases, Metabolic/blood , Case-Control Studies , Chronic Disease , Cholestasis, Intrahepatic/blood , Longitudinal Studies , Osteoprotegerin/blood , RANK Ligand/bloodالملخص
Renal Osteodystrophy [ROD] is a common complication in children with chronic renal failure. Osteoprotegerin [OPG] is a newly identified cytokine that plays an important role in bone metabolism. To assess OPG serum levels in children on hemodialysis with ROD and to investigate the correlation between OPG and intact parathyroid hormone [iPTH] serum levels. The present study was carried out on 50 children divided into 2 groups. Group I: included 30 children with ROD on regular hemodialysis who were subdivided into 2 subgroups according to iPTH serum values: Group IA: iPTH levels < 150 pg/ml. Group IB: iPTH levels > 300 pg/ml. Group II: included 20 apparentely healthy children served as control group with matched age and sex. All patients and controls were subjected to: 1- full history taking. 2-Thorough clinical examination. 3-laboratory investigations including: serum Ca, P, ALP, iPTH, and OPG. There was a highly significant increase in serum ALP, iPTH and OPG and significant decrease in serum Ca in patients than controls. There was a highly significant increase in serum ALP, iPTH and OPG and highly significant decrease in serum Ca in high iPTH group compared with low iPTH group. Serum Ca was significantly negatively correlated with serum iPTH while ALP and OPG were significantly positively correlated with serum iPTH. No correlation could be detected between serum P level and serum iPTH. Serum OPG combined with iPTH might be a useful marker in the non-invasive diagnosis of ROD in children with chronic renal failure at least in doubtful cases
الموضوعات
Humans , Male , Female , Renal Dialysis , Biomarkers , Osteoprotegerin/blood , Childالملخص
To assess subclinical atherosclerosis in patients with juvenile onset systemic lupus erythematosus [jSLE] with the carotid intima media thickness [cIMT] and investigate their relation to osteoprotegerin and traditional risk factors. The study included 25 jSLE patients and 10 age and sex- matched controls. All patients underwent full medical history, thorough clinical examination, disease activity evaluation with SLEDAI and routine laboratory investigations. Serum osteoprotegerin was measured in both patients and controls using ELISA technique. The cIMT was measured using ultrasonography. jSLE patients had higher cIMT in relation to controls yet the difference did not reach a statistical significance [0.56 +/- 0.35 mm versus 0.45 +/- 0.18 mm, p >/= 0.05]. There was an increased incidence of dyslipidemia in our patients. Patients had significantly higher serum OPG than controls 21[11] versus 11[9] pg/ml, p<0.05]. Correlations between cIMT, traditional risk factors, SLEDAI and osteoprotegerin were statistically insignificant [p>0.05 for all]. We found an increased atherosclerotic risk in jSLE patients as evidenced by increased cIMT and dyslipidemia, which necessitates ardent screening and prompt intervention to prevent life threatening complications in later years. Also, it seems likely that elevated circulating OPG levels in patients with jSLE represent an increased production of this molecule in response to inflammation yet its role as a marker of subclinical atherosclerosis in these patients is doubtful
الموضوعات
Humans , Male , Female , /etiology , Carotid Artery Diseases , Ultrasonography , Osteoprotegerin/blood , Risk Factorsالملخص
Recent evidences suggest that the activation of peroxisome proliferator-activated receptor (PPAR)-gamma, which is an important transcriptional factor in adipocyte differentiation, also plays an important role in the bone microenvironment. The objective of the study was to clarify whether Pro12Ala polymorphism was related to the serum OPG levels and bone mineral metabolism in healthy Korean women. In 239 Korean women (mean age 51 years), who participated in medical check-up program in a health promotion center, anthropometric measurements, lumbar spine and femoral neck bone mineral density (BMD), bone turnover markers, such as serum total alkaline phosphatase (ALP) levels, urine deoxypyridinoline levels, and 24-h urine calcium excretion were measured. Serum levels of OPG were measured with ELISA method. DNAs were extracted from the samples and the genotyping of the Pro12Ala polymorphism (rs1801282) in the PPAR-gamma gene was performed via an allelic discrimination assay using a TaqMan probe. In addition, we examined the haplotype analysis between two polymorphisms of PPAR-gamma gene, Pro12Ala in exon B and C161T in exon 6 (rs3856806). Allelic frequencies were 0.950 for Pro allele and 0.050 for Ala allele, which was in compliance with Hardy- Weinberg equilibrium, and there was no Ala12Ala genotype among the genotyped subjects. Mean serum OPG level was significantly lower (P=0.035), and serum total ALP was significantly higher (P=0.014) in the Pro12Ala genotype group compared with the Pro12Pro genotype group, which were consistently significant even after adjustment for weight, height, and serum follicle stimulating hormone (FSH). In multiple regression analysis with serum OPG as the dependent variable and age, weight, ALP, femoral neck BMD and Pro12Ala genotype included in the model, only Pro12Ala genotype was significant determinant of serum OPG level (beta=-0.136, P=0.035). The haplotype analysis with C161T polymorphism revealed that subjects with Ala and T alleles showed significantly lower serum OPG levels compared with those with Pro12Pro/CC genotype, which were consistently significant even after adjustment for age, weight, height and FSH (P=0.010). This result suggests statistically significant association of Pro12Ala polymorphisms with serum OPG levels in Korean females.
الموضوعات
Female , Humans , Middle Aged , Alanine/genetics , Amino Acid Substitution , Asian People , Bone Density/physiology , Bone and Bones/metabolism , Enzyme-Linked Immunosorbent Assay , Gene Frequency , Korea , Mutation , Osteoprotegerin/blood , PPAR gamma/genetics , Polymorphism, Genetic , Proline/geneticsالملخص
This study was carried out to evaluate the effect and the mechanism of action of melatonin on some bone markers in ovarectomized bone loss in rats. 32 female albino rats underwent either bilateral laparotomy [sham, n=8] or bilateral ovarectomy [Ovx, n=24]. The Ovx rats were divided into 3 groups, each of 8 rats; Vehicle-treated [Ovx], estrogen-treated [E2] and melatonin-treated [Mlt] group. After 14 weeks treatment, blood and urine were collected. Serum osteoprotegerin [OPG], inhibin, follistatin, and alkaline phosphatase [ALPase] were determined as bone markers. In addition, urinary Deoxypyridinoline [uDPD] was assayed. Serum OPG, inhibin and follistatin levels significantly decreased upon Ovx. They increased upon either treatment with E2 or Mlt with non- significant difference in between as compared to Ovx group. In addition, serum ALPase and uDPD significantly increased on Ovx and decreased with either therapy as compared to Ovx one with non- significant difference between both therapies. The results revealed that administration of Mlt inhibited high bone turnover and prevented calcium loss in ovarectomized rats. This may be through increasing OPG, inhibin and/or follistatin levels. Mlt could be a candidate for the treatment of postmenopausal osteoporosis